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Abstract
Since 1998, Bluetongue virus (BTV)-serotypes 1, 2, 4, 9, and 16 have invaded European countries around the Mediterranean
Basin. In 2006, a huge BT-outbreak started after incursion of BTV-serotype 8 (BTV8) in North-Western Europe. More recently,
BTV6 and BTV11 were reported in North-Western Europe in 2008. These latter strains are closely related to live-attenuated
vaccine, whereas BTV8 is virulent and can induce severe disease in ruminants, including cattle. In addition, Toggenburg
orbivirus (TOV) was detected in 2008 in Swiss goats, which was recognized as a new serotype of BTV (BTV25). The (re-
)emergency of known and unknown BTV-serotypes needs a rapid response to supply effective vaccines, and research to
study this phenomenon. Recently, orbivirus research achieved an important breakthrough by the establishment of reverse
genetics for BTV1. Here, reverse genetics for two recent BTV strains representing virulent BTV8 and avirulent BTV6 was
developed. For this purpose, extensive sequencing of full-genomes was performed, resulting in the consensus sequences of
BTV8/net07 and BTV6/net08. The recovery of ‘synthetic BTV’, respectively rgBTV8 and rgBTV6, completely from T7-derived
RNA transcripts was confirmed by silent mutations by which these ‘synthetic BTVs’ could be genetically distinguished from
wild type BTV, respectively wtBTV6 and wtBTV8. The in vitro and in vivo properties of rgBTV6 or rgBTV8 were comparable to
the properties of their parent strains. The asymptomatic or avirulent properties of rgBTV6 and the virulence of rgBTV8 were
confirmed by experimental infection of sheep. Reverse genetics of the vaccine-related BTV6 provides a perfect start to
develop new generations of BT-vaccines. Reverse genetics of the virulent BTV8 will accelerate research on the special
features of BTV8, like transmission by species of Culicoides in a moderate climate, transplacental transmission, and
pathogenesis in cattle.
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Introduction
Bluetongue virus (BTV) belongs to the family Reoviridae, genus
Orbivirus [1]. BTV-transmission between ruminants, including
cattle, sheep, and goats, occurs in majority by bites of species of
Culicoides. Bluetongue (BT) is listed as a ‘notifiable disease’ by the
Office International des Epizooties (OIE) [2] causing severe
hemorrhagic disease with fever, lameness, coronitis, swelling of the
head (particularly the lips and tongue) and death. There are 24
BTV-serotypes recognized as defined by cross neutralization
assays.
The genome of BTV consists of ten linear double-stranded
RNA genome segments Seg-1 to Seg-10 encoding structural
proteins VP1 to VP7, and nonstructural proteins, NS1, NS2 and
NS3/NS3a, for reviews see Roy et al. [3,4]. The virus particle
composes three shells of proteins, the inner shell consists of VP3
encoded by Seg-3, the middle shell consists of VP7 encoded by
Seg-7, and the outer shell is formed by VP2 (Seg-2) and VP5 (Seg-
6). The BTV-particle further contains three enzymatic proteins,
VP1 (Seg-1), VP4 (Seg-4) and VP6 (Seg-9), and one copy of each
of the ten genome segments Seg1 to Seg-10 in the inner shell. The
nonstructural proteins NS1, NS2, and NS3/3a encoded by Seg-5,
Seg-8, and Seg-10, respectively, are not part of the BTV particle.
Since 1998, BTV-serotypes 1, 2, 4, 9, and 16 have invaded
European countries around the Mediterranean Basin. In 2006, a
huge BT-outbreak started after incursion of BTV8/net06 (IAH
collection nr. BTV-8 NET2006/04) [5] in N-W Europe [6]. More
recently, BTV6 (BTV6/net08) and BTV11 were reported in N-W
Europe in 2008 [7,8,9]. Both BTV-strains are closely related to
live-attenuated vaccine strains (IAH collection nr. BTV-6
NET2008/05) [9,10] Further, a new BTV-member, Toggenburg
orbivirus (TOV), was detected in goats in Switzerland in 2008, and
is proposed to be the 25th serotype of BTV [11].
These incursions and the re-emergency of BTV-serotypes in
Europe are addressing the need for safe and effective vaccines, but
also for research on the recent development of Bluetongue in areas
with a moderate climate. Spread of Bluetongue is restricted to the
expansion of the competent vector, specific species of Culicoides.
BTV8/net06 must be transmitted by endemic European Culicoides
spp. [12,13,14], as the common vector C. imicola was not found in
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the affected area. Further, Bluetongue is generally believed to be a
‘sheep disease’, but BTV8/net06 is causing significant clinical
signs in cattle [15]. Finally, BTV8/net06 is passing the placenta of
pregnant heifers and ewes, although this is restricted to BT-
vaccines or cell-adapted BTV-strains [16]. It was therefore
suggested that BTV8/net06 should be related to a BT-vaccine
or a laboratory strain of BTV8. To study the specific properties of
BTV8/net06, a method to genetically manipulate BTV is
required. For BTV8/net06 and BTV6/net08, a genetic modifi-
cation system based on the uptake of a plasmid-derived T7-
transcript was published [17]. However, this system is not efficient,
laborious, and needs positive selection to remove wild type virus.
Recently reverse genetics was developed based on T7 RNA-
polymerase driven run-off transcripts for BTV1 [18]. This reverse
genetics system was successfully used to genetically modify BTV
[19,20,21]. The reverse genetics system offers many advantages,
like the efficient rescue of virus with fully defined genomes,
recovery of mutant viruses with delayed growth characteristics,
and tailor-made BTV-reassortants. Here the rescue of completely
‘synthetic’ virulent BTV8 (rgBTV8), and completely ‘synthetic’
avirulent BTV6 (rgBTV6) is described. Both ‘synthetic’ BTVs are
studied in sheep in order to confirm their properties compared to
their wild type strains, wtBTV8 and wtBTV6.
Materials and Methods
Cell lines and virus
BSR cells (a clone of BHK-21 cells; gift from Polly Roy, [22])
were cultured in Dulbecco’s modified Eagle’s medium (DMEM;
Invitrogen) containing 5% fetal bovine serum (FBS) and 1%
Penicillin/Streptomycin and Fungizone.
C. variipennis (KC) cells (gift from Linda McHolland, [23]) were
grown in modified Schneider’s Drosophila medium with 15% heat
inactivated fetal bovine serum, 4.5 mU/ml bovine insulin, 6 mg/
L reduced glutathione, 30 mg/L L-asparagine, 2 ml 7.5% sodium
bicarbonate and 2 mM L-glutamine to the medium of which the
pH is adjusted to 6.7–6.8 with 1N hydrochloric acid [23].
BTV8/net07 was isolated from the Holstein Frisian cow
NL441689187 from Bavel, the Netherlands, which was sampled
for export purposes on July 24th, 2007 [24]. Isolation from
EDTA-blood was performed on eggs (e1) and subsequent three
passages on BHK-21 cells (e1/bhk3) or subsequent three passages
on KC cells (e1/kc3). BTV6/net08 was isolated from the Holstein
Frisian cow NL415834681 (24th October 2008) from Heeten, the
Netherlands [7]. Isolation from EDTA-blood was performed on
eggs and subsequent three passages on BHK-21 cells and once on
BSR cells.
All virus stocks were obtained by infection of BSR cells at low
multiplicity of infection (MOI) and harvested after 100%
cytopathic effect (CPE) was observed. Virus titers were determined
by endpoint dilution and expressed as plaque forming units per ml.
Viral stocks were stored at 280uC.
Sequencing of BTV8/net07 and BTV6/net08
Embryonated egg-isolated BTV8/net07/e1, cell-culture derived
BTV8/net07/e1/bhk3, BTV8/net07/e1/kc3 and BTV6/net08/
e1/bhk3/bsr2 were send to C.A. Potgieter at Onderstepoort
Veterinary Institute (South Africa). BTV8/net07 and BTV6/
net08 genome segments Seg-1 to Seg-10 were sequenced after use
of an improved strategy for sequence-independent amplification of
segmented dsRNA viral genomes [25] and pyrophosphate-based
454 (Roche GS20/FLX) sequencing at the Inqaba Biotec
company (SA). Sequence analysis was essentially done as described
[25] using Lasergene8 from DNASTAR. Files containing the
sequence information, quality values and flowgrams (sff files) were
loaded into the Seqman 8 programme of the Lasergene software.
Contig sequences of BTV8 strains were checked manually and
compared to sequences of BTV-8nt(2006/04) [5] with genbank
accession numbers AM498051–AM498060) and to sequences of
BTV8/Neth2006 submitted by A.C. Potgieter ([25] with genbank
accession numbers FJ183374–FJ183383 for Seg-1 to Seg-10.
Consensus sequences of BTV8 directly isolated from EDTA-
blood were determined after RNA-isolation using the TRIZOL
method, and reverse transcription and amplification by a one-tube
system (Qiagen one-step RT-PCR kit). Overlapping DNA
amplicons were sequenced using BigDyeH Terminator v1.1 Cycle
Sequencing Kit in a ABI PRISMH 3130 Genetic Analyzer Applied
Biosystems.
Contig sequences of BTV6/net08 were checked manually and
compared to sequences of BTV6/Net2008/05 [10] with genbank
accession numbers QG506472–QG506481.
Construction of T7 plasmids with cDNA-inserts derived
from BTV genome segments
cDNA of genome segments were synthesized by Genscript
Corporation (Piscataway, NJ). Genome segments Seg-1 to Seg-10
of BTV1 were based on the sequences as submitted to Genbank
with accession numbers FJ969719–FJ969728 [18]. Genome
segments Seg-1 to Seg-10 of BTV8/net07 and of BTV6/net08
were based on the consensus sequences described in this paper.
cDNAs were cloned in pUC-derivatives, pUC18, 19 or 57, or
pJET1.2 under control of the T7 RNA-polymerase promoter and
a recognition site for a restriction enzyme at the 39-terminus for
defined run-off transcription (Figure 1, depicted from Boyce et al.,
[18]). Plasmids were maintained in E.coli DH5a, and were purified
using the QIAfilter Plasmid Midi Kit (Qiagen).
In vitro synthesis of BTV-transcripts
Plasmid DNA was digested at the 39-terminus with the
respective restriction enzyme, and was purified by standard
procedures. One mg digested plasmid DNA was used for in vitro
RNA run-off transcription with 59-cap analogue using the
MESSAGE mMACHINE T7 Ultra Kit (Ambion). In this
reaction, a ratio of 4:1 of anti-reverse cap analogue to rGTP
Figure 1. Schematic overview of plasmids containing a full-length BTV genome segment. A full-length BTV genome segment flanked by a
T7 promoter and an unique site for a restriction enzyme (here BsmBI is indicated as an example), which defines the BTV 39end sequence during
transcription (depicted from Boyce et al., [18]. The nucleotides of the ultimate 59- and 39-ends of the BTV genome segment are presented in bold
symbols. The sequence of the T7 promoter is italicized, and that of the unique site is underlined. The positions of the start of transcription and
digestion by restriction enzymes for run-off transcription are indicated by arrows.
doi:10.1371/journal.pone.0030540.g001
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was used. Synthesized RNA was purified by use of MEGAclear
columns (Ambion) according to the manufacturer’s instructions,
and eluted RNA was stored at 280uC.
Transfection of T7-derived RNA transcripts to rescue
‘synthetic’ BTV1, BTV6 and BTV8
Monolayers of 105 BSR cells per 2 cm2 were transfected with
equimolar amounts of RNA of BTV segments encoding VP1,
VP3, VP4, NS1, VP6, NS2. In total, 600 ng RNA was transfected
using 1 mg lipofectamineTM 2000 (1:2.5; 1 mg/ml Invitrogen) in
Opti-MEMH I Reduced Serum Medium according to manufac-
turer’s conditions. Eighteen to twenty hours post transfection,
monolayers were transfected again with 600 ng equimolar
amounts of ten RNA segments. At 4 hrs post transfection, the
transfection mix was replaced with 1 ml DMEM supplemented
with 5% FBS and 1% of Penicillin/Streptomycin/Fungizone.
Supernatants were harvested from monolayers developing cyto-
pathogenic effect (CPE) at 48 hrs after the second transfection.
BTV-specific CPE was confirmed by immunostaining of fixed
monolayers with monoclonal antibody (Mab) produced by ATCC-
CRL-1875 directed against VP7 according to standard proce-
dures. In case of monolayers without visible CPE, duplicate wells
were passed 1:5 to rescue virus from less efficiently transfected
monolayers. After incubation of three days, monolayers were
screened for CPE and VP7-expression as described above.
Characterization of rescued BTVs
Viral RNA of virus stocks was isolated from 200 ml of supernatant
with the High Pure Viral RNA kit (Roche). Genome segments Seg-2
and Seg-6 were identified by amplification of (parts of) the genome
segments with serotype-specific primers, which are listed in Table 1.
Template RNA (6 ml) was denaturated at 94uC for 3 min and
immediately cooled on ice. A one-step RT-PCR kit (Qiagen) was
used to reversely transcribe RNA and amplification of cDNA in a
RT-PCR containing both primers. The reaction mix contained
10 ml of 5xQIAGEN one-step RT-PCR buffer, 2 ml of dNTP mix,
0.6 mM of each primer and 2 ml of the enzyme mix (containing RT
and PCR reaction enzymes). RNase-free water was added to a total
volume of 44 ml. Six microliters of denatured RNAwas added to the
mix. The RNA was reversely transcribed at 45uC for 30 min. This
was followed by an activation step at 94uC for 15 min. Forty
amplification cycles were then carried out (94uC for 1 min, 45uC for
1 min and 72uC for 2 min), followed by a terminal extension step at
72uC for 10 min. The cDNA products were analyzed by 0.9%
agarose gel electrophoresis and visualized under UV light after
staining with ethidium bromide.
For Seg-10, the in-house developed serogroup-specific diagnos-
tic PCR-test was used [15]. Sequencing of amplicons was carried
out to discriminate between different Seg-10 sequences by using
the BigDyeH Terminator v3.1 Cycle Sequencing Kit in a ABI
PRISMH 3130 Genetic Analyzer (both supplied by Applied
Biosystems, Foster City, IA, USA).
Growth curves and plaque morphology of ‘synthetic’
BTV6 and 8 (rgBTV6 and rgBTV8)
Confluent BSR-monolayers in M24-well plates were infected in
duplicate at a multiplicity of infection (moi) of 0.1. After
attachment to cells for 1.5 h at 37uC, the medium was removed
and refreshed with 1 ml of DMEM with 5% FBS, 1% Penicillin/
Streptomycin/Fungizone and incubation was continued. At 24, 48
and 72 h post infection (hpi), samples of the supernatants were
harvested and stored at 280uC. Virus titers were determined by
plaque-titration on BSR cells. Therefore, BSR cells were infected
with tenfold dilutions of samples, and grown for 48 h under
EMEM overlay medium (containing 1% methylcellulose). Infec-
tious centers (hereafter referred to as plaques) were detected by
immunostaining with a VP7-specific Mab ATCC-CRL-1875.
Virus titers were expressed as pfu/ml.
To study plaque size, BSR monolayers were infected by tenfold
dilutions of indicated viruses, and grown for two days under
overlay medium (EMEM complete with 1% methylcellulose).
Monolayers were fixed with methanol/aceton (1:1) and immuno-
stained with Mab ATCC-CRL-1875. Plaques in appropriate
dilutions were compared.
Experimental infection with rgBTV6 and rgBTV8
All experiments with live animals were performed under the
guidelines of the European Community (86/609) and were
approved by the Committee on the Ethics of Animal Experiments
of the Central Veterinary Institute (Permit Number: 2011-003).
Sixteen female Blessumer sheep of 6–24 months old and free of
BTV and BTV-antibodies were commercially sourced from the
same flock of a Dutch farm. The sheep were randomly allocated to
four groups of four animals. On day 0 (0 dpi), a total of 1 ml of 105
TCID50/ml of wtBTV8 or rgBTV8 was administered subcutane-
ously to four sheep per virus between the shoulder blades left and
right from the spinal cord. Four sheep were intramuscularly
injected in the neck with 1 ml of 105 TCID50/ml rgBTV6. The
fourth group served as control group. EDTA-blood samples were
collected daily during the first week after inoculation and every
other day until the end of the trial at 21 dpi. Serum samples were
collected more frequently in the second week post inoculation.
Samples were tested by the in-house PCR-test for BTV [15] for
the detection of BTV RNA in EDTA-blood and by blocking
ELISA (ID-VET) for the detection of BTV-specific antibodies in
serum. Body temperature was recorded daily, and fever was
defined as the average temperature plus two times the standard
deviation. Clinical signs were recorded daily according to the
clinical score table for BTV8 animal trials (Table S1).
Clinical signs were quantified following challenge by an adapted
clinical reaction index (CRI) as described by Huismans [26]. A
maximum score of 12 was given to the cumulative total of fever
readings (a) as described above from days 3 to 14 post inoculation
(dpi), a clinical score according the clinical score table and
normalized to a maximum score of 12 (b). An additional 4 points
were added to the sum of a and b if death occurred within 14 dpi.
Results
Recovery of synthetic BTV1
Rescue of infectious BTV1 from all ten in vitro synthesized
RNAs has been previously demonstrated [18]. With the aim of the
Table 1. List of forward and reverse primers used for
amplification of (parts of) genome segment 2 of BTV6 and
BTV8.
primera sequence
expected amplicon size
(bp)
BTV8S2f GTTAAAATAGCGTCGCGATG 964
BTV8S2r6 GATGTTGGTACGCTCGTT
BTV6S2f8 TGATCCACGACTCAATGGAC 791
BTV-S2-2R TTTCTGATGCGATCAATG
aAll primers were supplied by Eurogentec b.v., Maastricht, Netherlands.
doi:10.1371/journal.pone.0030540.t001
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development of reverse genetics for BTV we started reproducing
this technique for BTV1. Synthesized and purified run-off
transcripts were used to rescue BTV1 according to the double
transfection protocol [21] with small modifications. Briefly, 2 cm2
of BSR-monolayers were transfected with in total 600 ng
equimolar amounts of RNA. Virus was directly harvested from
supernatant of transfected monolayers, or after passage of the
transfected monolayer in case no CPE was seen. In general, CPE
could be seen as early as 24 h post transfection, however,
supernatants were harvested at 48 h post transfection to increase
virus recovery. Monolayers were immunostained with VP7-
specific Mabs in order to check specificity of CPE. BTV1 was
efficiently rescued with a virus titer of about 106 pfu/ml.
Supernatant of transfected monolayers was used to prepare a
stock of ‘synthetic’ BTV1 by one passage on BSR cells.
Recovery of rgBTV8
cDNAs from genome segments Seg-1 to Seg-10 of BTV8/net06
were synthesized based on genbank accession numbers
AM498051–AM498060 [5]. However, new sequences became
available for this strain [25] showing differences with the
mentioned accession numbers. In order to start with a well-
documented strain of BTV8 we decided to extensively sequence
the BTV8-isolate of the first reported case in 2007 [24]. Consensus
sequences were determined of BTV8/net07/e1, BTV8/net07/
e1/bhk3, and BTV8/net07e1/kc3 by deep sequencing. Consensus
sequences were compared, and only in BTV8/net07/e1/kc3 two
nucleotide differences were found. In Seg-1 at nucleotide position
3277 CRT leads to amino acid change ARV and in Seg-2
position 1215ARG leads to amino acid change RRG. The
consensus sequences determined by deep sequencing of BTV8/
net07/e1 and BTV8/net07/e1/bhk3 were the same as that of
blood-derived BTV8/net07 which was determined by conven-
tional RTPCR and sequencing and compared to sequences of
BTV8/Neth2006 (Table 2).
No differences were found when the sequences were compared
to BTV8/Net2007/01 [10] with genbank accession numbers
GQ506451–GQ506460. However, fifty-five nucleotide differences
were found which were different either with BTV8/2006/04 [5]
or BTV8/2006 [25]. These differences resulted in 9 amino acid
changes in 6 different proteins and 11 changes in 5- or 39UTR’s.
The consensus sequence of BTV8/net07 was used to generate
cDNAs encoding the correct amino acid sequence and contain the
correct 59- and 39-UTR. Therefore, differences in the 59- and 39-
UTR and changes resulting in amino acid mutations in the
originally derived cDNAs (based on BTV8/Net2006) were
corrected by standard procedures with respect to the consensus
sequence from BTV8/net07. Consequently, 16 silent mutations
remained in cDNAs used for rescue of BTV8/net07.
T7 run-off transcripts from these corrected cDNAs were
transfected according to the modified double transfection protocol.
CPE appeared between 24–48 h after the second transfection. In
general, CPE seemed to be slightly delayed compared to BTV1.
To confirm the rescue of ‘synthetic’ BTV8 (rgBTV8), a
straightforward method was used to distinguish rgBTV8 from
wild type BTV8 (wtBTV8). A part of Seg-2 encompassing a SnaBI
recognition site that is specific for rgBTV8 (position 242) was
amplified by RT-PCR using primers btv8-S2f and btv8-S2r6.
Digestion by SnaBI of amplicons derived from wtBTV8 or
rgBTV8 resulted in fragments of 1000 bp or 760 and 240 bp
respectively (Fig. 2A, lane 1 wtBTV8 vs lane 2 rgBTV8). This
demonstrated that a SnaBI site was uniquely present in rgBTV8.
Successful digestion by XhoI confirmed the specificity, and
comparability of both amplicons (lane 3–4). The amplicons were
also sequenced using the btv8-S2f primer to indeed confirm the
introduction of this distinguishable sequence (Fig. 2B).
The genetic stability of rgBTV8 was studied by sequencing
the entire genome, except for the ultimate sequences at the 59-
and 39ends. RNA was isolated from the supernatant of the third
passage, sequenced by the described method, and compared to
sequences of the cDNAs used for rescue. Except for one silent
mutation in Seg-3 at nucleotide position 260, the determined
sequences of Seg-1 to Seg-10 were confirmed, including all silent
mutations. In conclusion, ‘synthetic’ BTV8 (rgBTV8) was
recovered, is genetically stable, and confirmed by the presence
of silent mutations in the RNA segments of rgBTV8. These
silent mutations, 17 in total, and divided over 6 genome
segments, are unique and distinguish rgBTV8 from wild type
BTV8 (wtBTV8).
Recovery of rgBTV6
Sequences of Seg1 to Seg-10 derived from BTV6/net08 e1/
bhk3/bsr1 were 100% identical with those of BTV6/Net2008/05
(accession numbers QG506472–QG506481) isolated by one
passage on KC cells and three passages on BHK-21 cells. These
consensus sequences were used for cDNA-synthesis. Two mutated
LguI recognition sites of which one was changed to an NlaIV-site
were introduced in the cDNA of Seg-2 without affecting the
encoded amino acid sequence.
T7 RNA-transcripts from the digested BTV6/net08 plasmids
were transfected according to the optimized protocol as
described. CPE appeared between 1–2 days post the second
transfection. The presence of rgBTV6 was confirmed by digestion
with NlaIV instead of the LguI at position 910 in Seg-2.
Therefore, a part of Seg-2 segments of rgBTV6 and wtBTV6,
encompassing the respective region were partially amplified by
RT-PCR using primers btv6-S2f8 and btv6-S2-2R. Digestion of
these amplicons demonstrated that an extra NlaIV site was
introduced in rgBTV6 compared to wtBTV6 (Fig. 3A, lanes 1
and 2). Digestion with LguI further confirmed that this
recognition site was present in wtBTV8 and mutated in rgBTV8
(Fig. 3A, lanes 3–4). Sequences of the respective amplicons indeed
confirmed the introduction of the distinghuishable, but silent,
mutation (Fig. 3B). In conclusion, ‘synthetic’ BTV6 (rgBTV6) was
recovered, and could be differentially identified by the presence
of silent mutations.
Characterization of rescued ‘synthetic’ BTVs rgBTV6 and
rgBTV8
To compare rgBTVs with wtBTVs, growth curves in BSR cells
were determined. Therefore, virus titers were measured at 24, 48,
and 72 hpi (Fig. 4A). Although at 24 hpi both rgBTV6 and
rgBTV8 grew to slightly lower virus titers (5,5.103 and
1,45.104 pfu/ml, respectively) than wtBTV6 or wtBTV8
(1,85.104 and 1,85.104 pfu/ml, respectively), the virus titer at
72 hpi was similar (Fig. 4A.,1,0.105 and 1,33.105 pfu/ml for
BTV6, and 9,0. 105 and 7,5.105 pfu/ml for BTV8).
Plaque morphology of the ‘synthetic’ viruses, rgBTV6 and
rgBTV8, grown under overlay medium for two days was similar to
that of the wtBTVs (Fig. 4B). In conclusion, rgBTV6 and rgBTV8
derived from ten in vitro synthesized T7 transcripts are
indistinguishable from wtBTV6 respectively wtBTV8 with respect
to growth characteristics in BSR cells. Furthermore, the
introduced silent mutations rgBTV6 (two mutations in Seg-2)
and in rgBTV8 (16 mutations in genome segments Seg-2, Seg-3,
Seg-4, Seg-5, Seg-6 and Seg-8) did not influence these growth
characteristics.
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Table 2. Sequence differences between strain BTV8/2007 and BTV8/Neth2006.
RNA segment nucleotide positiona
BTV8
Neth2006/04b
BTV8
Neth2006c
BTV8
Neth2007d amino acid changee Remarks
Seg-1 1128 t c c -
1226 g a g -
1454 g a a -
1491 c g g Q493E
2051 c c t -
2534 c c t -
2634 a a g T875A
3701 c c t -
3939 c a a - 39UTR
Seg-2 242 a a g -
443 g g a -
470 c c t -
1007 c c a -
2084 g a g -
Seg-3 38 g a a -
62 t a a -
113 c c t -
1328 t t c -
2471 c t t -
Seg-4 620 g g a -
1026 a a t M340L
1324 t g g F439G
1960 a g g - 39UTR
1969 c a a - 39UTR
1971 t g g - 39UTR
Seg-5 1432 c t c -
1639 c c t -
1768 t - t - 39UTR
Seg-6 19 c t t - 59UTR
144 a a g -
546 a a g -
1365 c c t -
1383 a g g -
Seg-8 194 g a a D59N
781 g a a -
1112 g - g 39UTR
Seg-9 11 - ta - 59UTR
22–24 cta gct gct L3A
141 g g a A43T
256–258 gac aga aga D81R
413 t t c A133V
863 g a a -
1020–1022 tct ctc ctc - 39UTR
1024 c t t - 39UTR
1041–1044 acat taca taca - 39UTR
aNucleotide position numbering from strain BTV8/Neth2007 (genbank accession numbers GQ506451–GQ506460).
bStrain BTV8/Neth2006/04 [5] has been isolated on KC cells and passaged one time on BHK21 cells before analysis. The sequences from the genome segments
correspond to genbank accession numbers AM498051–AM498060 for Seg-1 to Seg-10.
cStrain BTV8/Neth2006 [25] is the same strain as BTV8/Neth2006/04 but has been passaged 2 times extra on BHK21 cells. The sequences from the genome segments
correspond to genbank accession numbers FJ183374–FJ183383 for Seg-1 to Seg-10.
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Virulence of rescued ‘synthetic’ BTVs rgBTV6 and rgBTV8
All sheep of the control group remained negative by PCR, and
ELISA. None of the sheep in the control group developed fever
and only very mild clinical signs were observed, like nasal/ocular
discharge and upper airway distress. Sheep infected (i.m.) with
rgBTV6 developed very mild signs of BT (Fig. 5A), like loss of
appetite for one day, mild ocular lacrimation and upper airway
distress and/or nasal discharge for more than one day. All infected
sheep developed fever between days 8 and 11 post infection (p.i.)
and were PCR-positive for BTV from five dpi onwards the end
(21 dpi) (Fig. 5B). All infected sheep seroconverted in the blocking
ELISA (Fig. 5C) from 8 dpi onwards.
Sheep infected (s.c.) with wtBTV8 developed mild to moderate
clinical signs of BT (Fig. 5A). Except for one sheep, which had no
clinical signs at all, all sheep scored mild clinical signs as
mentioned for rgBTV6. More severe clinical signs were observed
from 9 dpi onwards. Two of the animals were listless, showed local
oedema and red mucous in the mouth for several days. All sheep
developed fever between 6 and 11 dpi. All sheep became PCR-
positive between day 3–6 dpi and remained PCR-positive until the
end of the trial (21 dpi) (Fig. 5B). Sheep seroconverted by ELISA
from 7 dpi onwards (Fig. 5C).
Sheep infected (s.c.) with rgBTV8 developed similar clinical
signs as the wtBTV8-infected sheep (Fig. 5A), except for one
sheep, which showed no clinical signs at all. One sheep died at
8 dpi. This sheep also showed moderate clinical signs like apathy,
salivation, red mucous in the mouth and conjunctivitis. All sheep
in this group developed fever between 8–10 dpi. All sheep were
tested PCR-positive from 3–9 dpi onwards (Fig. 5B), and
seroconverted for VP7 antibodies from 7 dpi onwards (Fig. 5C).
The sheep in both groups, infected with wtBTV8 and rgBTV8
which did not show clinical signs, developed fever, became PCR-
positive and seroconverted, which confirmed successful infection.
The adapted clinical reaction index (CRI) was determined for
each sheep and averaged for the different groups to further
quantify clinical signs in groups (in particular wt- and rgBTV8).
For the control group the CRI (mean 6 SE) was 1.160.4, for the
rgBTV6 group 3.960.8, for the wtBTV8 group 8.762.2 and for
rgBTV8 group the CRI was 7.963.3. This showed a significant
difference (p,0.01) between the control group and the inoculated
groups. There was also a significant difference in the CRI for
rgBTV6 and both BTV8-groups, although the variation in the
BTV8-groups was high. There was no significant difference in
CRI between the wtBTV8- and the rgBTV8 -group.
Blood samples were used to determine the sequence of parts of
Seg-2, as described above, and a part of Seg-3 for only rgBTV8
and wtBTV8. For all viruses, the determined sequences matched
the sequence of the BTV administered to the sheep.
Discussion
After comparison of available sequences of the European
BTV8, many differences were found between BTV8/Net2006/04
(KC1/BHK1; [5]), BTV8/Net2006/04 (KC1/BHK3; [25]) and
BTV8/Net2007/01 (KC1/BHK1; [10]). Since a correct sequence
is crucial to establish reverse genetics, it was decided to restart with
the well-documented BTV8 isolate of 2007.
For this purpose, the complete sequences were determined by
deep sequencing of three different strains originating from the
same BTV8-isolate from the same cow. In addition, to exclude
possible artefacts by the isolation procedure or the method of
sequencing, RNA of BTV8 was directly isolated from EDTA-
blood and almost completely sequenced by conventional
sequencing. Except for three passages in KC cells (BTV8/
net07/e1/kc3), the sequences of BTV8/net07/e1 and BTV8/
net07/e1/bhk3 completely match the sequence of the original
blood-isolate. Indeed, BTV8/net07/e1/bhk3 induces similar
dBTV8/net07/e1/bhk3 (described in this paper) was isolated on eggs and was further passaged 3 times on BHK21 cells before analysis. This sequence matches
completely to sequences determined by Maan et al (2010). See also footnote a.
eAmino acid position numbering from strain BTV8/Neth2007.
doi:10.1371/journal.pone.0030540.t002
Table 2. Cont.
Figure 2. Characterization of rgBTV8 containing a marker mutation. (A) SnaBI or XhoI digestion of Seg-2 RT-PCR products. SnaBI- or XhoI-
digested RT-PCR products amplified from isolated RNA of strains rg- and wtBTV8 (passage 3) with primers btv8-S2f and btv8-S2r6 were separated on
1,5% agarose gel. Lanes 1–2 SnaBI-digestion: lane 1, wtBTV8; lane 2, rgBTV8. Lanes 3–4 XhoI -digestion: lane 3, wtBTV8; lane 4, rgBTV8. Marker sizes (in
bp) are indicated on the right (TrackItTM 100 bp DNA ladder Invitrogen). Sizes of SnaBI-digested fragments are indicated on the left (in bp). (B)
Sequence electropherograms of the Seg-2 RT-PCR products of wt- and rgBTV8 including the Seg-2 SnaBI mutation in rgBTV8 at position 242
(nucleotide position in segment indicated above sequences).
doi:10.1371/journal.pone.0030540.g002
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clinical signs as the blood-isolate (manuscript in preparation). In
contrast, two differences were found after three passages in KC
cells, which could be involved in adaptation to this cell line.
Previously derived cDNAs were corrected with respect to this
consensus sequences, but the remaining 16 nucleotide differences
did not result in change of encoded amino acids or mutations in
UTR-sequences. Consequently, rescued virus harbours genetic
markers in six genome segments to identify the presence of
synthetic BTV8 (rgBTV8). It has been shown for Sindbis- and
poliovirus that silent mutations can affect the attenuation [27,28].
Similarly, remaining genetic differences could change the
characteristics of rgBTV8 compared to wtBTV8, but no
differences were observed in growth kinetics, plaque morphology
and virulence. It can therefore be concluded that these remaining
silent mutations had no effect on the characteristics of BTV8.
Furthermore, all silent mutations remained present in rgBTV
indicating that there is no strong positive selection pressure for
the original genetic background of BTV8/net07. Finally, one
extra silent mutation was found in Seg-3 at nucleotide position
260.
Except for Seg-7 and Seg-10 (no mutations), and Seg-2 and Seg-
3 (silent mutations), obvious (nonsilent) variations were found in all
other genome segments of BTV8/Neth2006 compared to the
consensus sequences of BTV8/Neth2007 and strains derived from
BTV8/net07, as listed in Table 2. Remarkably, all these genome
segments (Seg-1, -4, -5, -6, -8, and -9) showed variation in the
sequences of UTR-sequences, and some of these are located in the
highly conserved ‘‘ACTTAC’’ sequence [29]. Of course, these
differences could be involved in translation and/or replication of
the respective genome segment. In addition, genome segments
(Seg-1, -4, -8, and -9) showed variation in the encoded amino acid
sequences. For Seg-1, the amino acid (aa) difference at position
493 (Q493E) is located between the N-terminal domain (NTD:
residues 1–373) and the Polymerase domain (PD; residues 582–
882) of VP1. The other aa difference T875A is located within the
PD, but is located outside the conserved sequence motifs A–D [3]
Figure 4. Growth curve and plaque size of viruses rgBTV6, wtBTV6, rgBTV8 and wtBTV8. (A) BSR monolayers were infected in duplicate
by indicated viruses with 0.1 moi. At 24, 48 and 72 hours post infection, samples of 1 ml supernatant were taken. The virus titer in collected samples
were determined by plaque-titration, expressed as pfu/ml, and plotted at a logarithmic scale. The bars represent the averages and standard errors
from two replicates. (B) BSR monolayers were infected by indicated viruses in tenfold dilutions and grown for 2 days under overlay medium (EMEM
complete with 1% methylcellulose). Plaques in appropriate comparable dilutions are displayed.
doi:10.1371/journal.pone.0030540.g004
Figure 3. Characterization of rgBTV6 containing a marker mutation. (A) NlaIV or LguI digestion of Seg-2 RT-PCR products. NlaIV or LguI-
digested RT-PCR products amplified from isolated RNA of strains rg- and wtBTV6 (passage 3) with primers btv6-S2f8 and btv6-S2-2R were separated
on 1,5% agarose gel. Lanes 1–2 NlaIV-digestion: lane 1, wtBTV6; lane 2, rgBTV6. Lanes 3–4 LguI-digestion: lane 3, wtBTV6; lane 4, rgBTV6. Marker sizes
(in bp) are indicated on the left (TrackItTM 100 bp DNA ladder Invitrogen). (B) Sequence electropherograms of the Seg-2 RT-PCR products of wt- and
rgBTV6 including the Seg-2 LguI mutation in rgBTV6 at position 910 (nucleotide position in segment indicated above sequences).
doi:10.1371/journal.pone.0030540.g003
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at the end of the PD in the thumb region. For Seg-4, aa difference
M340L is located in the 2’OMT domain (residues 155–377) of
VP4. The aa difference F439G is located in the second region of
the N7MTase domain (residues 110–154 and 378–509). For Seg-
8, aa difference D59N is located in the N-terminal region of NS2
(1–115) which is involved in formation of viral inclusion bodies,
binding of ssRNAs, and replication. Finally, most aa differences
were found in Seg-9. These aa differences, M3L, A43T, D81R
and A133V are not located in any of the conserved motifs that are
characteristic for RNA helicases of the DExH type [30].
Summarizing, the cause and effect of these observed variations
in several determined sequences of closely related strains of
BTV8/Neth06 are unknown.
Most of the clinical signs associated to Bluetongue were
observed after experimental infection of sheep with BTV8, and
were consistent with clinical signs reported most frequently in the
field in 2006 [31]. The most prominent of these were fever,
apathy, erosions of the oral mucosa, salivation, local oedema and
some problems with feet. To minimize interbreed susceptibility to
BTV, sheep from the same flock were used. However, the severity
of the clinical signs varied within a group, with moderate clinical
signs in two of the sheep, but relatively mild (one sheep) to no
clinical signs in the other sheep.
For the BTV6/net08 the consensus sequence was determined of
BTV6/net08/e1/bhk3/bsr2 and was 100% identical to that of
BTV6/Neth2008/05 (E1/KC1/BHK1) [10]. Virus rgBTV6 was
synthesized based on this consensus sequence, except for two silent
mutations in Seg-2, which were introduced for differentiation
Figure 5. Experimental infection of sheep with viruses rgBTV6, rgBTV8 and wtBTV8. Four sheep per group were infected with 105 TCID50/
ml rgBTV6 (i.m.) or 105 TCID50/ml rg- or wtBTV8 (s.c.). (A) body temperatures (mean values per group; lines) and clinical scores (per group; bars) were
recorded daily. (B) the presence BTV genomic RNA was determined through a real-time Seg-10 RTPCR (mean values per group). (C) the presence of
BTV specific antibodies in serum samples was determined with a BTV-VP7 blocking Elisa (ID-VET) and the mean blocking percentage per group was
displayed as 100-value (sample).
doi:10.1371/journal.pone.0030540.g005
Table 3. Schematic overview of ‘synthetic’ reassortants
between rgBTV1 and rgBTV8.
Virus No Virus Namea Virus Segments
b
VP1 VP2 VP3 VP4 NS1 VP5 VP7 NS2 VP6 NS3
BTV104 BTV1/8 (5, 8) x x
BTV105 BTV1/8 (2, 5, 8) x x x
BTV106 BTV1/8 (4, 5, 8) x x x
BTV107 BTV1/8 (5, 6, 8) x x x
BTV108 BTV1/8 (5, 7, 8) x x x
BTV109 BTV1/8 (5, 8, 9) x x x
BTV110 BTV1/8 (5, 8, 10) x x x
aThe segments derived from BTV8 are shown between brackets.
bVirus segments coding for indicated proteins from BTV8 are shown by an ‘‘x’’.
doi:10.1371/journal.pone.0030540.t003
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between rgBTV6 and wtBTV6. In fact, BTV6/net08 is likely a
reassortant of two live-attenuated vaccines, since 9 out of 10
genome segments are almost identical (99.7 to 100%) to these of
live-attenuated vaccine for serotype 6 (MLV6), whereas the
variable genome segment Seg-10 showed the greatest identity
(98.4%) to that of MLV2 (RSAvvv2/02) [10]. Indeed, BTV6/
net08 hasn’t shown obvious clinical signs in the field and after
experimental infection [8,32]. Furthermore, transmission of
BTV6/net08 was very low in N-W European conditions resulting
in a natural decline, and finally BTV6/net08 disappeared in the
winter of 2008/2009 without control measures were undertaken.
Similar growth characteristics of wtBTV6 and rgBTV6 were
observed (Fig. 4), and the absence of virulence of rgBTV6 was
similar to previous observations after experimental infection of
sheep, the most susceptible and sensitive ruminant for Bluetongue.
This vaccine-related BTV6/net08 caused fever in all sheep, but
showed very mild clinical signs in sheep compared to rgBTV8/
net07.
Reverse genetics was developed for two recent field isolates of
BTV, the virulent strain of BTV8 and the vaccine-related strain of
BTV6. These BTV-isolates differ in many aspects, like serotype,
virulence, pathogenesis in sheep and cattle, and transmission by
Culicoides species which are endemic for N-W European countries
with a moderate climate. Reverse genetics can be used to generate
desired reassortants of these different viruses. Reassortment is a
natural process of viruses with a segmented genome. Reassortants
have also been described for BTV for a long time (reviewed in
[33]). However, these ‘natural’ reassortants will arise by positive
selection, even in cell culture. Previously, we have used this process
by transfection of synthetic RNA in a BTV-infected cell, followed
by screening for the desired ‘synthetic’ resassortant meaning with
the synthetic genome segment [17]. However, this method was not
very efficient and limits the possibilities. Reverse genetics can
increase this method by formation of sets of desired genome
segments for rescue of viable BTV. Even less fit virus will be
rescued due to the absence of negative selection. In order to
investigate this application, we have rescued multiple reassortants
of BTV1 and BTV8 during the process of developing reverse
genetics (Table 3). These reassortants were all viable indicating the
flexibility of combination of sets of ten genome segments of BTV1
and BTV8.
However the ‘synthetic’ BTVs, rgBTV6 and BTV8, are
genotypically distinguishable from their ‘ancestor’ viruses,
BTV6/net08 and BTV8/net06, these ‘synthetic BTVs’ are
phenotypically indistinguishable from their ‘ancestors’ as studied
for several in vitro parameters and virulence in sheep. Other
aspects, including transplacental transmission and replication in
the vector, are not studied in detail yet. Reverse genetics as genetic
modification system, here demonstrated by the introduction of
many silent mutations, will be a powerful tool for in-depth
investigations by site-directed mutagenesis of viral genes involved
in these intriguing phenomena of bluetongue virus and other
orbiviruses.
Supporting Information
Table S1 Clinical score table BTV animal trial. The
clinical signs described in this table were based on findings in the
field [31] as well as experimental data [15] and scored daily
depending on severity from 0–3 points during 3–15 days post
inoculation.
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